DICER protein expression is significantly decreased in the absence of MOV10 and FMRP. حسب Monica C. Lannom (11772729)

rHSP60 decreases LPS-induced mononuclear cell proliferation. حسب Igor Emiliano L. Souza (18196495)

TREM1 inhibition decreases HIV mediated inflammatory cytokine production. حسب Jinhee Hyun (6900683)

S5 Fig - حسب Jordan K. Abbott (8934239)

Diabetic wounds show increased amounts of vessel leakage and decreased pericyte coverage. حسب Uzoagu A. Okonkwo (8754933)

Inhibition of PKC or Rho protein kinase decreases Ad5 wild type replication <i>in vitro</i>. حسب Alice Liu (4814415)

Decreased reductase activity and increased round body formation in the <i>gpsA</i> mutant. حسب Dan Drecktrah (36180)

The spectral sensitivity of European seabass fed a 5% taurine diet. حسب Richard W. Brill (2337940)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات: